Radiotherapy after high-dose chemotherapy followed by autologous bone marrow transplantation in patients with intermediate or high-grade non-Hodgkin's lymphoma

Research output: Contribution to journalArticle

Abstract

Patients with intermediate or high-grade non-Hodgkin's lymphoma are rarely cured of their disease after the failure of conventional therapy. Autologous bone marrow transplantation (ABMT) offers such patients a new possibility of cure. Our purpose was to evaluate the usefulness of radiotherapy in these patients who did not achieve complete remission of disease after high-dose chemotherapy (HDCT) followed by ABMT or who had previous bulky disease. In this study we examined 10 patients: after HDCT + ABMT, 9 patients had persistent disease and 1 patient with previous bulky disease was in complete remission. All patients underwent involved-field radiotherapy administered by a 6-18 MV linear accelerator, total mean dose 4000 cGy (range, 3200-5000 cGy). At the end of radiotherapy we observed 6 complete responses and 4 progressions of disease outside the radiotherapy field. No serious side effects were observed. To date, of the 6 complete responses 2 have relapsed (after 9 and 11 months) and 4 are alive and disease free at 24 months (range, 8-39 months) after radiotherapy. In our opinion, radiotherapy is an effective treatment after HDCT + ABMT and may have a role in a prospective multidisciplinary approach.

Original languageEnglish
Pages (from-to)335-338
Number of pages4
JournalTumori
Volume82
Issue number4
Publication statusPublished - Jul 1996

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
Radiotherapy
Drug Therapy
Particle Accelerators
Disease Progression
Therapeutics

Keywords

  • autologous bone marrow transplantation
  • non-Hodgkin's lymphoma
  • radiotherapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

@article{3738f6ad32dd4b7cb9b7aec4a8908ca2,
title = "Radiotherapy after high-dose chemotherapy followed by autologous bone marrow transplantation in patients with intermediate or high-grade non-Hodgkin's lymphoma",
abstract = "Patients with intermediate or high-grade non-Hodgkin's lymphoma are rarely cured of their disease after the failure of conventional therapy. Autologous bone marrow transplantation (ABMT) offers such patients a new possibility of cure. Our purpose was to evaluate the usefulness of radiotherapy in these patients who did not achieve complete remission of disease after high-dose chemotherapy (HDCT) followed by ABMT or who had previous bulky disease. In this study we examined 10 patients: after HDCT + ABMT, 9 patients had persistent disease and 1 patient with previous bulky disease was in complete remission. All patients underwent involved-field radiotherapy administered by a 6-18 MV linear accelerator, total mean dose 4000 cGy (range, 3200-5000 cGy). At the end of radiotherapy we observed 6 complete responses and 4 progressions of disease outside the radiotherapy field. No serious side effects were observed. To date, of the 6 complete responses 2 have relapsed (after 9 and 11 months) and 4 are alive and disease free at 24 months (range, 8-39 months) after radiotherapy. In our opinion, radiotherapy is an effective treatment after HDCT + ABMT and may have a role in a prospective multidisciplinary approach.",
keywords = "autologous bone marrow transplantation, non-Hodgkin's lymphoma, radiotherapy",
author = "Salvina Barra and Almalina Bacigalupo and Renzo Corv{\`o} and Marina Guenzi and Tindaro Scolaro and Vito Vitale",
year = "1996",
month = "7",
language = "English",
volume = "82",
pages = "335--338",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - Radiotherapy after high-dose chemotherapy followed by autologous bone marrow transplantation in patients with intermediate or high-grade non-Hodgkin's lymphoma

AU - Barra, Salvina

AU - Bacigalupo, Almalina

AU - Corvò, Renzo

AU - Guenzi, Marina

AU - Scolaro, Tindaro

AU - Vitale, Vito

PY - 1996/7

Y1 - 1996/7

N2 - Patients with intermediate or high-grade non-Hodgkin's lymphoma are rarely cured of their disease after the failure of conventional therapy. Autologous bone marrow transplantation (ABMT) offers such patients a new possibility of cure. Our purpose was to evaluate the usefulness of radiotherapy in these patients who did not achieve complete remission of disease after high-dose chemotherapy (HDCT) followed by ABMT or who had previous bulky disease. In this study we examined 10 patients: after HDCT + ABMT, 9 patients had persistent disease and 1 patient with previous bulky disease was in complete remission. All patients underwent involved-field radiotherapy administered by a 6-18 MV linear accelerator, total mean dose 4000 cGy (range, 3200-5000 cGy). At the end of radiotherapy we observed 6 complete responses and 4 progressions of disease outside the radiotherapy field. No serious side effects were observed. To date, of the 6 complete responses 2 have relapsed (after 9 and 11 months) and 4 are alive and disease free at 24 months (range, 8-39 months) after radiotherapy. In our opinion, radiotherapy is an effective treatment after HDCT + ABMT and may have a role in a prospective multidisciplinary approach.

AB - Patients with intermediate or high-grade non-Hodgkin's lymphoma are rarely cured of their disease after the failure of conventional therapy. Autologous bone marrow transplantation (ABMT) offers such patients a new possibility of cure. Our purpose was to evaluate the usefulness of radiotherapy in these patients who did not achieve complete remission of disease after high-dose chemotherapy (HDCT) followed by ABMT or who had previous bulky disease. In this study we examined 10 patients: after HDCT + ABMT, 9 patients had persistent disease and 1 patient with previous bulky disease was in complete remission. All patients underwent involved-field radiotherapy administered by a 6-18 MV linear accelerator, total mean dose 4000 cGy (range, 3200-5000 cGy). At the end of radiotherapy we observed 6 complete responses and 4 progressions of disease outside the radiotherapy field. No serious side effects were observed. To date, of the 6 complete responses 2 have relapsed (after 9 and 11 months) and 4 are alive and disease free at 24 months (range, 8-39 months) after radiotherapy. In our opinion, radiotherapy is an effective treatment after HDCT + ABMT and may have a role in a prospective multidisciplinary approach.

KW - autologous bone marrow transplantation

KW - non-Hodgkin's lymphoma

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029803228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029803228&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 335

EP - 338

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -